^
Association details:
| Biomarker: | PD-L1 amplification |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Published date:
01/18/2021
Excerpt:
In patients with TNBC, exploratory analyses showed that the HR for durvalumab efficacy (OS) was 0.18 (95% CI: 0.05–0.71; log-rank test, P = 0.0059) in patients with CD274 gain/amplification (n = 23)...Exploratory analyses identified CD274 amplification as a potential biomarker of sensitivity.
DOI:
10.1038/s41591-020-01189-2
Source:
Title:
128O - PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial
Published date:
05/24/2020
Excerpt:
Among pts with TN tumors, durvalumab was associated to a better OS in the gain/amplification subgroup (HR 0.18, 95%CI 0.05-0.71 ), compared to the neutral/loss subgroup (HR 1.1, 95%CI 0.47-2.6 )....This exploratory subgroups analysis of the first randomized trial comparing a PDL1 inhibitor to chemotherapy in the maintenance setting shows that PDL1 CNA could be an important predictive marker for PD(L)1 inhibitors efficacy.
Trial ID:
